Maintenance: On Thursday, June 28 2018, 18:00-18:15, maintenance work on the ZORA servers is scheduled. ZORA will not be available during this period. Thank you for your patience.
Widenmeyer, M; Griesemann, H; Stevanović, S; Feyerabend, S; Klein, R; Attig, S; Hennenlotter, J; Wernet, D; Kuprash, D V; Sazykin, A Y; Pascol, S; Stenzl, A; Gouttefangeas, C; Rammensee, H G (2012). Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. International Journal of Cancer, 131(1):140-149.